TORONTO, May 1, 2024 /CNW/ - RIV Capital Inc. ("RIV Capital" or the "Company") (CSE: RIV) (OTC: CNPOF), an acquisition and investment firm with a focus on building a leading multi-state platform with one of the strongest portfolios of brands in key strategic U.S. markets, today applauds reports that the U.S. Drug Enforcement Agency proposes to reschedule cannabis under the Controlled Substance Act (the "CSA") from Schedule I to a Schedule III substance. A rescheduling of cannabis under the CSA is expected to lead to the removal of 280E taxes, provide additional tailwinds to support further federal reform, expand institutional access to invest in the cannabis sector, and accelerate opportunities for research into the medical benefits of cannabis.
Read more at newswire.cahello world
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
